^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    Apply
    A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (AdvanTIG-206) (NCT04948697)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    08/20/2021
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (ECOG-ACRIN 5103) (NCT00433511)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/02/2007
    Primary completion :
    01/07/2014
    Completion :
    02/22/2025
    HER-2 • ER
    |
    Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • cyclophosphamide intravenous
    SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. (NCT06835179)
    Phase 2
    The First Affiliated Hospital with Nanjing Medi...
    Not yet recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/01/2025
    Primary completion :
    02/01/2027
    Completion :
    05/01/2027
    BRAF
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    Niraparib Versus Bevacizumab As Maintenance Therapy in Patients with De Novo Ovarian Cancer Without Homologous Recombination Deficiency (OVNI-B) (NCT06827353)
    Phase N/A
    Centre Hospitalier Universitaire de Nīmes
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    10/01/2020
    Primary completion :
    05/31/2025
    Completion :
    09/30/2025
    BRCA
    |
    Avastin (bevacizumab) • Zejula (niraparib)
    Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (NCT00217737)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    09/06/2005
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    MSI • MSH2
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (NCT06023862)
    Phase 2
    Yonsei University
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    01/22/2024
    Primary completion :
    08/31/2027
    Completion :
    12/31/2029
    MSI • PD-1 • WT1
    |
    Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin
    Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) (NCT05482516)
    Phase 3
    Georgetown University
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/29/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    CD4
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA) (NCT03836066)
    Phase 2
    Fundación GECP
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    05/15/2019
    Primary completion :
    10/21/2024
    Completion :
    10/21/2024
    TMB
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (NCI-2022-09458) (NCT05627635)
    Phase 1/2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    05/03/2023
    Primary completion :
    10/07/2025
    Completion :
    10/07/2025
    POLE
    |
    POLE mutation
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (NCT02891824)
    Phase 3
    ARCAGY/ GINECO GROUP
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    09/22/2016
    Primary completion :
    10/15/2021
    Completion :
    02/22/2024
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • doxorubicin liposomal
    CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA (NCT05299476)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    04/16/2022
    Primary completion :
    01/20/2025
    Completion :
    06/01/2025
    HER-2 • PD-L1
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer (NCT06123884)
    Phase 2/3
    Bio-Thera Solutions
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    12/13/2023
    Primary completion :
    09/01/2026
    Completion :
    01/01/2027
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Avzivi (bevacizumab-tnjn) • BAT1308
    Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (NCT05200260)
    Phase 2
    Shanghai Gynecologic Oncology Group
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/13/2022
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    HRD • BRCA
    |
    HRD
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • docetaxel • Zejula (niraparib)
    Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (NCT03203525)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/23/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PIK3CA • PTEN
    |
    PIK3CA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • Torisel (temsirolimus) • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal
    Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC (NCT06817525)
    Phase 2
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/06/2024
    Primary completion :
    11/06/2025
    Completion :
    11/06/2025
    CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1
    |
    Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)
    Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (NCT02884648)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    11/15/2016
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    MUC16
    |
    Avastin (bevacizumab)
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (NCT01081262)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/12/2010
    Primary completion :
    02/25/2015
    Completion :
    03/01/2025
    KRAS
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • capecitabine • oxaliplatin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (CALGB 40603) (NCT00861705)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/15/2009
    Primary completion :
    08/01/2014
    Completion :
    02/22/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • cyclophosphamide intravenous
    Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases (CAIRO5) (NCT02162563)
    Phase 3
    Dutch Colorectal Cancer Group
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/01/2014
    Primary completion :
    07/01/2022
    Completion :
    01/01/2025
    BRAF • RAS
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (NCT04958811)
    Phase 2
    Georgetown University
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/21/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    ALK • ROS1
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer (NCT02138617)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    05/01/2014
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    UGT1A1
    |
    UGT1A1*1*1
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (CALGB-40503) (NCT00601900)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/24/2008
    Primary completion :
    06/30/2014
    Completion :
    05/30/2025
    ER • PGR
    |
    ER expression
    |
    Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)
    A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION) (NCT04732598)
    Phase 3
    Japanese Foundation for Cancer Research
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    01/21/2021
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    HER-2 • PD-L1
    |
    HR positive • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (NCT01814501)
    Phase 2
    John Hays
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2013
    Primary completion :
    08/06/2018
    Completion :
    08/06/2018
    KRAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients (NCT05468359)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/07/2022
    Primary completion :
    06/01/2032
    Completion :
    06/01/2037
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • cyclophosphamide
    Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa) (NCT01878422)
    Phase 3
    Istituto Scientifico Romagnolo per lo Studio e ...
    Completed
    Last update posted :
    01/31/2025
    Initiation :
    11/01/2007
    Primary completion :
    03/01/2014
    Completion :
    06/11/2016
    KRAS
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer (NCT05999812)
    Phase 2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/19/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2028
    BRAF • MSI • MLH1 • MSH6 • MSH2 • CD4
    |
    BRAF V600E • BRAF V600 • RAS wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    Study of Bevacizumab in Combination with Chemoimmunotherapy and Atezolizumab in Patients with Extensive Stage Small Cell Lung Cancer and Liver Metastases (BELIEVE) (NCT05588388)
    Phase 2
    Kamya Sankar
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    07/15/2024
    Primary completion :
    12/28/2026
    Completion :
    12/28/2027
    EGFR
    |
    EGFR mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (Liberty-201) (NCT05609370)
    Phase 1/2
    BeiGene
    Active, not recruiting
    Last update posted :
    01/01/2025
    Initiation :
    01/29/2023
    Primary completion :
    04/15/2026
    Completion :
    04/15/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • alcestobart (LBL-007)
    A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC (NCT03511963)
    Phase 3
    Shanghai Henlius Biotech
    Completed
    Last update posted :
    12/31/2024
    Initiation :
    04/09/2018
    Primary completion :
    04/15/2020
    Completion :
    04/20/2023
    BRAF
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Hanbeitai (bevacizumab biosimilar)
    Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study (Better Brain) (NCT06728865)
    Phase 2
    Li-kun Chen
    Recruiting
    Last update posted :
    12/11/2024
    Initiation :
    09/04/2024
    Primary completion :
    02/01/2028
    Completion :
    02/01/2028
    EGFR
    |
    EGFR mutation
    |
    Avastin (bevacizumab) • Ivesa (firmonertinib)
    Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab (NCT02436993)
    Phase 2
    University of California, Irvine
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    04/01/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive • HER-2 negative
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab)
    A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC (PM8002-B004C-TNBC-R) (NCT05918133)
    Phase 1/2
    Biotheus Inc.
    Recruiting
    Last update posted :
    12/03/2024
    Initiation :
    07/01/2022
    Primary completion :
    10/30/2026
    Completion :
    10/30/2026
    HER-2 • PGR
    |
    HER-2 negative • ER negative
    |
    albumin-bound paclitaxel • BNT327
    Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer (NCT06550453)
    Phase 4
    yangjianjun
    Recruiting
    Last update posted :
    11/12/2024
    Initiation :
    09/01/2024
    Primary completion :
    01/15/2025
    Completion :
    01/15/2026
    BRAF
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
    Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (NCI-2012-01247) (NCT01684397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    11/06/2024
    Initiation :
    11/21/2012
    Primary completion :
    05/02/2025
    Completion :
    05/02/2025
    CXCL8
    |
    Avastin (bevacizumab) • pazopanib
    A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    10/30/2024
    Initiation :
    11/10/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    BRCA
    |
    BRCA mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)
    NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study (NEOCATS) (NCT06650709)
    Phase 2
    British Columbia Cancer Agency
    Not yet recruiting
    Last update posted :
    10/23/2024
    Initiation :
    11/01/2024
    Primary completion :
    05/01/2026
    Completion :
    11/01/2028
    BRCA
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab)
    A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) (ASTRUM-015) (NCT04547166)
    Phase 2/3
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    10/17/2024
    Initiation :
    03/10/2021
    Primary completion :
    09/24/2025
    Completion :
    12/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)
    Hyperpolarized 13C-MRI in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab (NCT06605664)
    Phase 2
    Chang Gung Memorial Hospital
    Not yet recruiting
    Last update posted :
    09/24/2024
    Initiation :
    09/30/2024
    Primary completion :
    06/30/2029
    Completion :
    09/30/2031
    ITGAM
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma (NCT06590844)
    Phase 4
    Anhui Provincial Hospital
    Active, not recruiting
    Last update posted :
    09/11/2024
    Initiation :
    12/19/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    PD-L1
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab)